FrancophonIA/ELRC3.0 huggingface dataset:
English: In July 2011, the CHMP was concerned that Sumatriptan Galpharm in the non-prescription setting was not approvable.
Slovenian: Julija 2011 je imel odbor CHMP zadržke, da ne more podpreti izdajanja zdravila Sumatriptan Galpharm brez recepta.
English: Sumatriptan Galpharm was expected to work in the same way as the reference medicine, Imigran.
Slovenian: Zdravilo Sumatriptan Galpharm naj bi delovalo enako kot referenčno zdravilo Imigran.
English: Sumatriptan Galpharm was to be made available without prescription.
Slovenian: Izdaja zdravilo Sumatriptan Galpharm naj bi bila brez recepta.
English: How is Sumatriptan Galpharm expected to work?
Slovenian: Kako naj bi zdravilo Sumatriptan Galpharm delovalo?
English: What was Sumatriptan Galpharm expected to be used for?
Slovenian: Za kaj naj bi se zdravilo Sumatriptan Galpharm uporabljalo?
English: This summary was last updated in 03-2015.
Slovenian: Povzetek je bil nazadnje posodobljen 03-2015.
English: The company is also carrying out an observational study on the long-term safety of the medicine.
Slovenian: Družba trenutno izvaja tudi opazovalno študijo o dolgotrajni varnosti zdravila.
English: It is available as tablets (500 micrograms).
Slovenian: Na voljo je v obliki tablet (500 mikrogramov).
English: FEV1 is the most air a person can breathe out in one second.
Slovenian: FEV1 je največja količina zraka, ki jo oseba lahko izdihne v eni sekundi.
English: What measures are being taken to ensure the safe and effective use of Daliresp?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Daliresp?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Daliresp on 28 February 2011.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Daliresp, veljavno po vsej Evropski uniji, izdala 28. februarja 2011.
English: At the beginning of the study, both groups of patients had an FEV1 of around 1 litre (1,000 ml).
Slovenian: Na začetku študije sta imeli obe skupini bolnikov vrednost FEV1 okoli 1 litra (1 000 ml).
English: This benefit was seen on top of the effects of the treatments that the patients were already receiving.
Slovenian: Korist je bila vidna kot dodatek učinkom zdravljenj, ki so jih bolniki že prejemali.
English: The full EPAR for Daliresp can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Daliresp je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The patients could continue to receive treatment with a bronchodilator during the study.
Slovenian: Bolniki so med študijo lahko nadaljevali zdravljenje z bronhodilatorjem.
English: This is a summary of the European public assessment report (EPAR) for Daliresp.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Daliresp.
English: Patients may need to take Daliresp for several weeks before it starts to have an effect.
Slovenian: Bolniki morajo jemati zdravilo Daliresp več tednov, preden se pokaže njegov učinek.
English: This authorisation was based on the authorisation granted to Daxas in 2010 (‘informed consent').
Slovenian: Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom Daxas, ki je bilo izdano leta 2010 (uporaba dokumentacije s soglasjem).
English: Daliresp must not be used in patients who have moderate or severe problems with their liver.
Slovenian: Zdravila Daliresp ne smejo uporabljati bolniki z zmernimi ali hudimi težavami z jetri.
English: In addition, the company that makes Daliresp will ensure that healthcare professionals who will prescribe the medicine in all Member States of the European Union (EU) are provided with educational materials containing information on the medicine's side effects and how it should be used.
Slovenian: Poleg tega bo družba, ki izdeluje zdravilo Daliresp, zagotovila, da bodo v vseh državah članicah Evropske unije (EU) zdravstveni delavci, ki bodo predpisovali zdravilo, prejeli izobraževalno gradivo o neželenih učinkih zdravila in njegovi uporabi.
English: For more information about treatment with Daliresp, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Daliresp preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Other information about Daliresp
Slovenian: Druge informacije o zdravilu Daliresp
English: In addition, the patients who took Daliresp had an average of 1.1 moderate or severe flare-ups of their disease, compared with 1.4 flare-ups in the patients who took placebo.
Slovenian: Poleg tega so imeli bolniki, ki so jemali zdravilo Daliresp, v povprečju 1,1 zmernega ali hudega izbruha bolezni v primerjavi z 1,4 izbruha pri bolnikih, ki so jemali placebo.
English: The company will also provide cards for patients, telling them what information that they need to give their doctor about their symptoms and past illnesses to help the doctor know whether Daliresp is appropriate for them.
Slovenian: Zagotovila bo tudi kartice za bolnike z informacijami, ki jih morajo sporočiti zdravniku o simptomih in preteklih boleznih, da bo ta lahko presodil, ali je zdravilo Daliresp zanje primerno.
English: After considering all of the available data on the effects of the medicine, the Committee decided that Daliresp's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor je ob upoštevanju vseh razpoložljivih podatkov o učinkih zdravila zaključil, da so koristi zdravila Daliresp večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: Daliresp is not used on its own but as an ‘add-on' to treatment with bronchodilators (medicines that widen the airways in the lungs).
Slovenian: Zdravilo Daliresp se ne uporablja samostojno, ampak kot „dodatek“ k zdravljenju z bronhodilatorji (zdravili, ki širijo dihalne poti v pljučih).
English: Daliresp is a medicine that contains the active substance roflumilast.
Slovenian: Daliresp je zdravilo, ki vsebuje zdravilno učinkovino roflumilast.
English: The card will include an area where patients can record their weight.
Slovenian: Na kartici bo tudi prostor, kjer bodo bolniki lahko beležili svojo telesno maso.
English: A risk management plan has been developed to ensure that Daliresp is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Daliresp je bil pripravljen načrt obvladovanja tveganj.
English: The active substance in Daliresp, roflumilast, belongs to a group of medicines called ‘phosphodiesterase type 4 (PDE4) inhibitors'.
Slovenian: Zdravilna učinkovina v zdravilu Daliresp, roflumilast, spada v skupino zdravil, ki jih imenujemo „zaviralci fosfodiesteraze tipa 4 (PDE4)“.
English: What benefit has Daliresp shown during the studies?
Slovenian: Kakšne koristi je zdravilo Daliresp izkazalo med študijami?
English: By blocking the action of PDE4, roflumilast reduces the inflammation in the lungs, helping to reduce the patient's symptoms or to prevent them from getting worse.
Slovenian: Ker roflumilast zavira delovanje PDE4, zmanjša vnetje pljuč, kar pripomore k zmanjšanju bolnikovih simptomov ali prepreči njihovo poslabšanje.
English: Because patients taking Daliresp may lose weight, they are advised to weigh themselves on a regular basis.
Slovenian: Ker lahko bolniki, ki jemljejo zdravilo Daliresp, shujšajo, jim je treba svetovati redno tehtanje.
English: The most common side effects with Daliresp (seen in between 1 and 10 patients in 100) are decreased weight, decreased appetite, insomnia (difficulty sleeping), headache, diarrhoea, nausea (feeling sick) and abdominal pain (stomach ache).
Slovenian: Najpogostejši neželeni učinki zdravila Daliresp (opaženi pri 1 do 10 bolnikih od 100) so zmanjšana telesna masa, zmanjšan tek, nespečnost (motnje spanca), glavobol, driska, navzeja (slabost) in bolečine v trebuhu.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Daliresp.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: The main measure of effectiveness was the improvement in forced expiratory volumes (FEV1) and the reduction in the number of moderate or severe flare-ups of their COPD over a year of treatment.
Slovenian: Glavno merilo učinkovitosti je bilo izboljšanje forsiranega ekspiracijskega volumna (FEV1) in zmanjšanje števila zmernih ali hudih izbruhov kronične obstruktivne pljučne bolezni v enem letu zdravljenja.
English: After a year, the patients who took Daliresp had an average increase of 40 ml while those given placebo had an average decrease of 9 ml.
Slovenian: Po enem letu so imeli bolniki, ki so jemali zdravilo Daliresp, v povprečju 40 ml večjo vrednost FEV1, medtem ko se je pri tistih, ki so prejemali placebo, ta vrednost zmanjšala za 9 ml.
English: What is the risk associated with Daliresp?
Slovenian: Kakšna tveganja so povezana z zdravilom Daliresp?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Daliresp, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: The tablets should be swallowed with water at the same time each day.
Slovenian: Priporočeni odmerek zdravila Daliresp je ena tableta enkrat na dan. Tablete je treba pogoltniti z vodo vsak dan ob isti uri.
English: The CHMP noted that there was a need for new COPD treatments and that the main studies showed a modest benefit of Daliresp in patients with severe COPD.
Slovenian: CHMP je ugotovil, da obstaja potreba po novih načinih zdravljenja kronične obstruktivne pljučne bolezni in da sta glavni študiji pokazali skromno korist zdravila Daliresp pri bolnikih s hudo kronično obstruktivno pljučno boleznijo.
English: Daliresp has been compared with placebo (a dummy treatment) in two main studies involving over 3,000 adults with severe COPD who had had at least one flare-up of their disease in the past year.
Slovenian: Zdravilo Daliresp so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, v kateri je bilo vključenih več kot 3 000 odraslih bolnikov s hudo kronično obstruktivno pljučno boleznijo, ki so imeli najmanj en izbruh bolezni v preteklem letu.
English: Daliresp is used to treat severe chronic obstructive pulmonary disease (COPD) in adults who have chronic bronchitis (long-term inflammation of the airways), and whose COPD flares up frequently.
Slovenian: Zdravilo Daliresp se uporablja za zdravljenje hude kronične obstruktivne pljučne bolezni (KOPB) pri odraslih bolnikih, ki imajo kronični bronhitis (dolgotrajno vnetje dihalnih poti) in pri katerih se izbruhi kronične obstruktivne pljučne bolezni pogosto pojavijo.
English: Why has Daliresp been approved?
Slovenian: Zakaj je bilo zdravilo Daliresp odobreno?
English: COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing air in and out of the lungs.
Slovenian: Kronična obstruktivna pljučna bolezen je dolgotrajna bolezen, pri kateri se dihalne poti in pljučni mešički poškodujejo ali zamašijo, kar oteži vdihavanje in izdihavanje zraka.
English: How has Daliresp been studied?
Slovenian: Kako je bilo zdravilo Daliresp raziskano?
English: For the full list of all side effects reported with Daliresp, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Daliresp, glejte navodilo za uporabo.
English: What is Daliresp used for?
Slovenian: Za kaj se zdravilo Daliresp uporablja?
English: It blocks the action of the PDE4 enzyme, which is involved in the inflammation process that leads to COPD.
Slovenian: Zavira delovanje encima PDE4, ki sodeluje pri vnetju, kar povzroči kronično obstruktivno pljučno bolezen.
English: Daliresp was shown to be more effective than placebo at treating COPD.
Slovenian: Zdravilo Daliresp je bilo učinkovitejše od placeba pri zdravljenju bolnikov s kronično obstruktivno pljučno boleznijo.
English: What is Daliresp?
Slovenian: Kaj je zdravilo Daliresp?
English: The doctor may stop treatment with Daliresp if the patient loses too much weight.
Slovenian: Če bolnik izgubi preveč telesne mase, se bo zdravnik morda odločil, da prekine zdravljenje z zdravilom Daliresp.
English: How is Daliresp used?
Slovenian: Kako se zdravilo Daliresp uporablja?
English: How does Daliresp work?
Slovenian: Kako zdravilo Daliresp deluje?
English: These side effects occurred in more than 1 in 4 patients.
Slovenian: Ti neželeni učinki so se pojavili pri več kot 1 od 4 bolnikov.
English: Further information on Braftovi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Nadaljnje informacije o zdravilu Braftovi so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Braftovi (encorafenib)
Slovenian: Braftovi (enkorafenib)
English: Braftovi is available as capsules (50 mg and 75 mg).
Slovenian: Zdravilo Braftovi je na voljo v obliki kapsul (50 mg in 75 mg).
English: Braftovi (encorafenib) EMA/570410/2018
Slovenian: Braftovi (enkorafenib) EMA/570410/2018
English: What measures are being taken to ensure the safe and effective use of Braftovi?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Braftovi?
English: The European Medicines Agency therefore decided that Braftovi's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Braftovi večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: For the full list of side effects and restrictions, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev glejte navodilo za uporabo.
English: Patients who took this combination lived on average for nearly 15 months without the disease getting worse.
Slovenian: Bolniki, ki so se zdravili s to kombinacijo, so brez poslabšanja bolezni povprečno preživeli skoraj 15 mesecev.
English: Patients normally take 450 mg (six 75 mg capsules) once a day but can have the dose reduced or treatment stopped temporarily if they experience troublesome side effects.
Slovenian: Bolniki navadno vzamejo 450 mg (šest kapsul po 75 mg) enkrat dnevno, vendar se ta odmerek lahko zmanjša ali zdravljenje začasno prekine, če se pri bolniku pojavijo neprijetni neželeni učinki.
English: As for all medicines, data on the use of Braftovi are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Braftovi stalno spremljajo.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Braftovi have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Braftovi upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Braftovi is a medicine for treating melanoma (a skin cancer) that has spread or cannot be removed by surgery.
Slovenian: Braftovi je zdravilo, ki se uporablja za zdravljenje melanoma (kožnega raka), ki se je razširil ali ga ni mogoče odstraniti s kirurškim posegom.
English: What benefits of Braftovi have been shown in studies?
Slovenian: Kakšne koristi zdravila Braftovi so se pokazale v študijah?
English: Other information about Braftovi
Slovenian: Druge informacije o zdravilu Braftovi
English: Side effects reported with Braftovi are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Braftovi, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: Why is Braftovi authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Braftovi odobreno v EU?
English: Treatment with Braftovi can last for as long as the patient is benefiting from it and does not have unacceptable side effects.
Slovenian: Zdravljenje z zdravilom Braftovi traja, dokler ima bolnik od njega korist in se pri njem ne pojavljajo nesprejemljivi neželeni učinki.
English: The most common side effects with Braftovi and binimetinib taken together at the highest recommended doses are tiredness, nausea (feeling sick), diarrhoea, vomiting, retinal detachment (an eye problem that leads to poor vision), abdominal pain, joint pain, muscle pain and high levels of an enzyme called creatine kinase, which may indicate muscle problems.
Slovenian: Najpogostejši neželeni učinki kombinacije zdravila Braftovi in binimetiniba pri največjih priporočenih odmerkih so utrujenost, navzeja (slabost), driska, bruhanje, odstop mrežnice (težava z očmi, ki privede do poslabšanja vida), bolečine v trebuhu, bolečine v sklepih, bolečine v mišicah in povečane vrednosti encima, imenovanega kreatin kinaza, kar lahko kaže na težave z mišicami.
English: An overview of Braftovi and why it is authorised in the EU
Slovenian: Pregled zdravila Braftovi in zakaj je odobreno v EU
English: Up to 50% of patients with metastatic melanoma have a mutation in BRAF with the V600 mutation being the most common.
Slovenian: Do 50 % bolnikov z metastatskim melanomom ima mutacijo beljakovine BRAF, med katerimi je mutacija V600 najpogostejša.
English: For more information about using Braftovi, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Braftovi glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: What is Braftovi and what is it used for?
Slovenian: Kaj je zdravilo Braftovi in za kaj se uporablja?
English: It contains the active substance encorafenib.
Slovenian: Zdravilo vsebuje učinkovino enkorafenib.
English: A study of 577 patients with melanoma with the BRAF V600 mutation that had spread or could not be removed surgically showed that Braftovi with binimetinib can prolong the length of time patients lived without their disease getting worse.
Slovenian: Študija pri 577 bolnikih z melanomom z mutacijo BRAF V600, ki se je razširil ali ga ni bilo mogoče odstraniti s kirurškim posegom, je pokazala, da lahko kombinacija zdravila Braftovi in binimetiniba podaljša obdobje, ki ga bolniki preživijo brez poslabšanja bolezni.
English: What are the risks associated with Braftovi?
Slovenian: Kakšna tveganja so povezana z zdravilom Braftovi?
English: Braftovi can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in prescribing cancer medicines.
Slovenian: Predpisovanje in izdaja zdravila Braftovi je le na recept, zdravljenje pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje s predpisovanjem zdravil za zdravljenje raka.
English: The dose of the other medicine, binimetinib, may also be reduced but if binimetinib is stopped Braftovi must be stopped too.
Slovenian: Odmerek druge učinkovine, binimetiniba, se prav tako lahko zmanjša, vendar je treba v primeru prekinitve zdravljenja z binimetinibom prekiniti tudi zdravljenje z zdravilom Braftovi.
English: This encourages cancers to develop by allowing uncontrolled division of cells.
Slovenian: To omogoči nenadzorovano delitev celic in s tem razvoj raka.
English: The side effects seen with Braftovi are similar to those seen with other medicines in the same class and are considered manageable.
Slovenian: Neželeni učinki zdravila Braftovi so podobni neželenim učinkom drugih zdravil istega razreda in veljajo za obvladljive.
English: Braftovi in combination with binimetinib can help prolong the time that these patients live without their disease getting worse.
Slovenian: Zdravilo Braftovi lahko skupaj z binimetinibom pomaga podaljšati čas, ki ga bolniki preživijo brez poslabšanja bolezni.
English: The active substance in Braftovi, encorafenib, works by blocking the BRAF protein thereby stopping its activation by MEK and slowing down the growth and spread of the cancer.
Slovenian: Učinkovina v zdravilu Braftovi, enkorafenib, deluje tako, da zavira beljakovino BRAF in s tem prepreči aktivacijo beljakovin MEK, s čimer upočasni rast in širjenje raka.
English: In melanoma tumours with the BRAF V600 mutation, an abnormal form of the protein BRAF is present, which switches on another protein called MEK involved in stimulating cell division.
Slovenian: Pri melanomskih tumorjih z mutacijo BRAF V600 je prisotna nenormalna oblika beljakovine BRAF, ki aktivira drugo beljakovino, imenovano MEK, ki sodeluje pri spodbujanju delitve celic.
English: Braftovi is used in combination with another medicine, binimetinib (Mektovi), and is only for patients whose cancer cells have a specific mutation (change) in their genes called 'BRAF V600'.
Slovenian: Zdravilo Braftovi se uporablja v kombinaciji z učinkovino binimetinib (zdravilom Mektovi), in sicer samo pri bolnikih, ki imajo rakave celice s posebno gensko mutacijo (spremembo), imenovano BRAF V600.
English: How is Braftovi used?
Slovenian: Kako se zdravilo Braftovi uporablja?
English: How does Braftovi work?
Slovenian: Kako zdravilo Braftovi deluje?
English: This compared with over 9.5 months for patients who took encorafenib alone and just over 7 months for patients taking a different medicine called vemurafenib.
Slovenian: Tisti bolniki, ki so jemali samo enkorafenib, so brez poslabšanja bolezni preživeli 9,5 meseca, bolniki, ki so jemali drugo učinkovino, vemurafenib, pa zgolj nekaj več kot sedem mesecev.
English: Content (concentration)
Slovenian: Stična ovojnina Vsebina (koncentracija)
English: Wash hands after use.
Slovenian: Po uporabi si umijte roke.
English: Food increases the bioavailability to 80 to 90%.
Slovenian: Hrana poviša biodostopnost od 80% do 90 %.
English: ATCvet code: QC09BA07.
Slovenian: oznaka ATC vet: QC09BA07.
English: Très le Bois
Slovenian: Tres le Bois
English: Each chewable tablet contains:
Slovenian: Vsaka žvečljiva tableta vsebuje:
English: Do not use in dogs intended or used for breeding.
Slovenian: Ne uporabite pri psih, ki se jih uporablja ali so namenjeni za vzrejo.
English: 22600 Loudéac
Slovenian: 22600 Loudeac
English: 6.2 Major incompatibilities
Slovenian: 6.2 Inkompatibilnosti
English: The result is an improvement in heart function.
Slovenian: Rezultat je izboljšanje srčne funkcije.
English: However, this very slight decrease was transient, the red cell mass remained within the normal range, and the finding was not considered to be of clinical importance.
Slovenian: Ta zelo zmeren padec je bil prehodnega značaja, masa rdečih krvnih celic je ostala znotraj normale in ugotovitev ne šteje za klinično pomembno.
English: This is thought to be due to activation of feedback mechanisms without adverse clinical consequence.
Slovenian: To naj bi se pojavilo zaradi aktivacije povratnih mehanizmov brez neželenih kliničnih posledic.
English: It also allowed a quicker improvement of cough and activity and a slower degradation of cough, heart sounds and appetite.
Slovenian: Prav tako je opaženo hitrejše izboljšanje kašlja in aktivnosti in počasnejša degradacija kašlja, srčnih zvokov in apetita.
English: D-73614 Schorndorf Germany
Slovenian: D-73614 Schorndorf Nemčija
English: Do not use during pregnancy and lactation (see section 4.7).
Slovenian: Ne uporabite v obdobju brejosti in laktacije (glej poglavje 4.7).
English: Distribution
Slovenian: Distribucija